Eurosys develops and manufactures complete continuous-flow chemistry solutions, including precision continuous-flow microreactors, automated multi-step synthesis systems, and custom high-end core components. The company operates a multidisciplinary R&D organization and a FLOW R&D lab that collaborates with Tsinghua University and other research teams to support process development, scale-up and embedded-module systems. It offers a wide set of services—equipment design, R&D outsourcing, process optimization, scale-up research, precision manufacturing and training—focused on transferring lab results to pilot-plant scale. Eurosys emphasizes scalability and industrialization of continuous processes and has launched multiple continuous automatic synthesis and embedded-module products. Its technology targets customers across pharma, chemicals, catalysts, new energy, semiconductors and research, and the company reports partnerships with hundreds of domestic and international leading firms. The article cites industry advantages for continuous processing (cost savings of roughly 10–50%, production-cycle cuts of over half, and lower waste/carbon emissions) and notes the company has continued revenue growth and opened overseas markets. Founded in January 2015 and headquartered in Beijing, Oushisheng designs and supplies end‑to‑end continuous‑flow microreaction solutions including pumps, microreactors, online analysis and automation modules. Its product portfolio includes a patented high‑pressure, corrosion‑resistant dual‑syringe pump, the H‑Flow automatic microreactor hydrogenation instrument and the O‑Flow ozone reaction instrument, targeting lab‑to‑production scale‑up. The company emphasizes modular, standardized and intelligent products and is building toward AI‑assisted end‑to‑end chemical synthesis and a full “weapon‑library” of flow chemistry modules. Oushisheng reports nearly 500 cumulative customers, including industry leaders such as WuXi AppTec, Lonza and 凯莱英, with a customer repurchase rate above 40%. Management says performance has grown rapidly, reportedly doubling annually over the three pandemic years, and it holds multiple invention patent filings tied to core components. The company also maintains applied development labs and collaborations with Tsinghua University, Harbin Institute of Technology (Shenzhen) and the CAS Suzhou Drug Research Institute to advance its technology and applications.

Total raised

$7M

Funding rounds

2

Latest round

Equity

Latest activity

Apr 2023